Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 3/20 | 0.48 |
| ▸ | DRD2 | P14416 | 3/20 | 0.44 |
| ▸ | DRD4 | P21917 | 3/20 | 0.44 |
| ▸ | DRD3 | P35462 | 3/20 | 0.44 |
| ▸ | PPARA | Q07869 | 4/20 | 0.43 |
| ▸ | PPARG | P37231 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.40 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.40 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.38 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.38 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5106193 | 0.77 | DRD2 (0.51) | FFAR1DRD2DRD4DRD3PPARA | |
| SCHEMBL4033223 | 0.77 | FFAR1 (0.47) | FFAR1DRD2DRD4DRD3PPARA | |
| SCHEMBL3871816 | 0.76 | FFAR1 (0.43) | FFAR1PPARAPPARGHDAC4HDAC7 | |
| SCHEMBL4034904 | 0.76 | DRD2 (0.54) | FFAR1DRD2DRD4DRD3PPARA | |
| SCHEMBL5105819 | 0.75 | DRD2 (0.51) | FFAR1DRD2DRD4DRD3PPARA | |
| SCHEMBL27682910 | 0.74 | DRD2 (0.49) | FFAR1DRD2DRD4DRD3PPARA | |
| SCHEMBL14045323 | 0.73 | FFAR1 (0.41) | FFAR1DRD2DRD4DRD3PPARA | |
| SCHEMBL4747041 | 0.72 | FFAR1 (0.72) | FFAR1DRD2DRD4DRD3PPARA | |
| SCHEMBL27323764 | 0.70 | FFAR1 (0.50) | FFAR1DRD2DRD4DRD3PPARA | |
| SCHEMBL17047898 | 0.70 | ACP1 (0.45) | FFAR1PPARAPPARGALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE40558-E1 | Therapeutic uses of di-aryl acid derivatives | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2008-10-28 | — | — | US | disclosed |
| EP-1611083-B1 | SYNTHESIS OF 2-CHLOROMETHYL-6-METHYLBENZOIC ACID ESTERS | SANOFI AVENTIS DEUTSCHLAND (DE) | 2007-10-03 | — | — | EP | disclosed |
| EP-1177187-B1 | DI-ARYL ACID DERIVATIVES AS PPAR RECEPTOR LIGANDS | SANOFI AVENTIS DEUTSCHLAND (DE) | 2007-07-25 | — | — | EP | disclosed |
| US-6989462-B2 | Synthesis of 2-chloromethyl-6-methylbenzoic ester | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2006-01-24 | — | — | US | disclosed |
| EP-1611083-A1 | SYNTHESIS OF 2-CHLOROMETHYL-6-METHYLBENZOIC ACID ESTERS | Sanofi-Aventis Deutschland GmbH (DE) | 2006-01-04 | — | — | EP | disclosed |
| WO-2004085377-A1 | SYNTHESIS OF 2-CHLOROMETHYL-6-METHYLBENZOIC ACID ESTERS | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2004-10-07 | — | — | WO | disclosed |
| US-20040192956-A1 | Synthesis of 2-chloromethyl-6-methylbenzoic ester | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-09-30 | — | — | US | disclosed |
| US-6635655-B1 | Agonists or antagonists of peroxisome proliferator-activated receptors | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2003-10-21 | — | — | US | disclosed |
| EP-1177187-A1 | DI-ARYL ACID DERIVATIVES AS PPAR RECEPTOR LIGANDS | Aventis Pharma Deutschland GmbH (DE) | 2002-02-06 | — | — | EP | disclosed |
| WO-2000064888-A1 | DI-ARYL ACID DERIVATIVES AS PPAR RECEPTOR LIGANDS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2000-11-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040192956-A1 | Synthesis of 2-chloromethyl-6-methylbenzoic ester | PPARA, PPARG, PPARD | FFAR1 13/4885DRD2 1621/4885DRD4 1886/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.